NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC

CompletedN/A

Sponsor: CHA University

Conditions: Advanced Hepatocellular Carcinoma

Interventions: Atezolizumab plus bevacizumab

Countries: South Korea

Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related deaths globally and in Korea. Many patients diagnosed at advanced stage, and systemic therapy is mainstay of treatment in patients with advanced HCC. However, immune-checkpoint inhibitor (ICI) monotherapy did not significantly improve overall survival in phase III studies. According to previous retrospective analyses, ICI treatment in advanced HCC showed different organ-specific responses. The intrahepatic HCC was the least responsive organ to ICI treatment. The failure of phase III trials of ICI monotherapy may have been attributed to different organ-specific response pattern of ICIs. Combination of atezolizumab plus bevacizumab is expected to overcome the immunosuppressive microenvironment of liver and may enhance intrahepatic response of ICI.

Eligibility overview

Sex: ALL

Age: 19 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Confirmed HCC pathological or non-invasive assessment according to American Association for the Study of Liver Diseases (AASLD) criteria
* ECOG performance status 0 or 1
* Patients who received Atezolizumab and Bevacizumab combination therapy as first-line systemic treatment for unresectable HCC
* Barcelona Clinic Liver Cancer (BCLC) stage B or C
* Child-Pugh class A
* Measurable lesion
* Adequate hematologic and organ function

Exclusion Criteria:

* History of autoimmune disease
* Concomitant anticoagulation at therapeutic doses. Low dose aspirin for
* cardio protection is permitted.

Locations (1)

Seongnam-si, Gyeonggi-do, South Korea